A cross-sectional survey of hospitalization and blood tests implementation status in patients who received tolvaptan under 75 years of age using a Japanese claims database

CONCLUSIONS: Our results highlight the deviation from Japanese package insert recommendations. This approach can be applied to other drugs and provides important perspectives on pharmacovigilance research.PMID:34225550 | DOI:10.1080/14740338.2021.1951219

Source: Expert Opinion on Drug Safety - July 6, 2021 Category: Drugs & Pharmacology Authors: Shungo Imai Kenji Momo Hitoshi Kashiwagi Yuki Sato Takayuki Miyai Mitsuru Sugawara Yoh Takekuma Source Type: research